Castleark Management LLC Apellis Pharmaceuticals, Inc. Transaction History

Castleark Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$76.68 - $93.31 $3.13 Million - $3.81 Million	40,820 New	40,820 $3.72 Million
Q3 2022 Nov 15, 2022	BUY	$44.76 - $69.66 $2.59 Million - $4.03 Million	57,890 New	57,890 $3.95 Million
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $1.88 Million - $2.88 Million	-53,130 Closed	0 $0
Q4 2021 Feb 16, 2022	BUY	$30.74 - $49.16 $1.63 Million - $2.61 Million	53,130 New	53,130 $2.51 Million
Q2 2020 Aug 14, 2020	SELL	$24.8 - $38.49 $3.65 Million - $5.66 Million	-147,165 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$17.91 - $44.33 $2.64 Million - $6.52 Million	147,165 New	147,165 $3.94 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Castleark Management LLC, based on Form 13F filings with the SEC.

Stay updated on Castleark Management LLC with notifications on news.